Session information

Oral Presentation

(A) Pharmaceutical Chemistry

[30-413-pm] Drug design 4

Sat. Mar 30, 2024 2:15 PM - 3:15 PM [Room 413] Conference Center 413 (4F)

Chair: Kohei Tsuji, Kensuke Okuda

+Add all to schedule

2:15 PM - 2:27 PM

[30-413-pm06S] Discovery of pyrilamine-based hydroxamate derivatives as cell-membrane permeable HDAC6 inhibitors

○Hinako Amano¹, Seiya Hiranaka¹, Akihumi Shikida¹, Akiko Nakata², Mayumi Arata², Takashi Ito², Akihiro Ito², Minoru Yoshida², Kazuto Nunomura³, Soichiro ide⁴, Yasuo Nagaoka¹, Takaaki Sumiyoshi¹ (1. Grad. Sch. Sci. Eng., Kansai Univ., 2. RIKEN CSRS, 3. Grad. Sch. Pharm. Sci., Osaka Univ, 4. Tokyo Metro. Inst. Med. Sci)

2:27 PM - 2:39 PM

[30-413-pm07S] Depelopment of a novel TGR5 agonist with hypoglycemic effect and its potential as antidiabetic agent

○Syuhei Akutagawa¹, Chinami Imanishi¹, Yukiko Yamashita¹, Keisuke Oda¹, Yusuke Iguchi¹, Akira Matsuda¹, Yorimitsu Kodama¹, Mizuho Une¹ (1. Grad. Sch. Pharm. Sci., Hiroshima International Univ.)

2:39 PM - 2:51 PM

[30-413-pm08S] Myostatin-selective inactivation based on novel on/off-switchable photooxygenation catalyst

○Kaoru Ikekawa¹, Hideyuki Okamoto¹, Shuko Amber Murano¹, Jo Yamamoto¹, Sho Konno¹, Akihiro Taguchi¹, Atsuhiko Taniguchi¹, Yoshio Hayashi^1,2 (1. Sch. Pharm., Tokyo Univ. Pharm. Life Sci., 2. Sch. Life. Sci., Tokyo Univ. Pharm. Life Sci.)

2:51 PM - 3:03 PM

[30-413-pm09S] Design, synthesis and anticancer activity of cyclometalated Iridium(Ⅲ) complex-peptide hybrid that have a cationic cyclic peptide

○Nozomi Narushima¹, Arisa Koyamada¹, Kenta Yokoi¹, Shin Aoki^1,2 (1. Grad. Sch. Pharm. Sci., Tokyo Univ. of Science, 2. Res. Inst. for Sci. & Tech., Tokyo Univ. of Science)

3:03 PM - 3:15 PM

[30-413-pm10] Targeting transcription factors with PROTACS: the FOXM1 protein

○Carlos A Velázquez¹, Gordon Chan², Adam Karpf³, Antonio Vega-Medina¹, Erika Loredo-Calderon¹ (1. Fac. Pharm. & Pharm. Sci., U. of A., 2. Fac. Med. Dent., U. of A., 3. Univ. Nebraska, Med. Centre.)